AEON Biopharma Inc - Class A
Research AEON Biopharma Inc - Class A (AEON) on Bullrun: market cap USD 5.58M. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerAEON
- ExchangeNYSE MKT
- CountryUnited States
- SectorHealthcare
- IndustryBiotechnology
- CurrencyUSD
- Market capUSD 5.58M
- Financial periodQ1 2026
- RevenueUSD 0
- Net income-USD 11.79M
- Free cash flow-USD 12.04M
Valuation Snapshot
latest market cap is USD 5.58M.
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | USD 0 | -USD 39.22M | -USD 17.31M | n/a | -3.95 | USD 3.01M | USD 35.75M | -USD 55.03M |
| FY2024 | USD 0 | USD 42.01M | -USD 20.29M | n/a | 72.93 | USD 13.00K | USD 12.96M | -USD 28.57M |
| FY2023 | n/a | -USD 384.63M | n/a | n/a | -668.7 | USD 5.16M | USD 52.00K | -USD 153.04M |
| FY2022 | n/a | -USD 52.56M | -USD 35.89M | n/a | -0.38 | USD 9.75M | USD 131.79M | -USD 287.50M |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-08-25 | USD 5.58M | n/a | n/a | n/a |
| 2025 | 2025-12-31 | USD 13.32M | n/a | n/a | n/a |
| 2024 | 2024-12-31 | USD 21.60M | 8.4 | n/a | n/a |
| 2023 | 2023-12-29 | USD 267.55M | n/a | n/a | n/a |
About AEON Biopharma Inc - Class A
AEON Biopharma, Inc., a clinical stage biopharmaceutical company, focuses on developing botulinum toxins. It develops ABP-450 (prabotulinumtoxinA) injection for debilitating medical conditions, which completed Phase 2 study for the treatment of cervical dystonia and has an ongoing Phase 2 study for the treatment of chronic and episodic migraine. It also develops ABP-450 for the treatment of gastroparesis and post-traumatic stress disorder.
Related stock research
Other Healthcare stocks
Frequently asked questions
What is AEON Biopharma Inc - Class A's market cap?
AEON Biopharma Inc - Class A's market capitalization is USD 5.58M.
What does AEON Biopharma Inc - Class A do?
AEON Biopharma, Inc., a clinical stage biopharmaceutical company, focuses on developing botulinum toxins. It develops ABP-450 (prabotulinumtoxinA) injection for debilitating medical conditions, which completed Phase 2 study for the treatment of cervical dystonia and has an ongoing Phase 2 study for the treatment of chronic and episodic migraine. It also develops ABP-450 for the treatment of gastroparesis and post-traumatic stress disorder. The company has license agreements Daewoong Pharmaceutical Co., LTD., and Viatris Inc. The company is based in Irvine, California.